Lupin Picks Up Canadian Approval For Enbrel Biosimilar
Rymti Version Of Etanercept Is Third Rival To Be Approved By Health Canada
Lupin has celebrated the Canadian approval for its Rymti (etanercept) biosimilar, with all indications matching reference product Enbrel. The product represents the third version of Enbrel approved in Canada.
